due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized ...

(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share ...

HOUSTON, July 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2025 revenue of $130,200,000. Core's operating income was $15 ...

HOUSTON, Oct. 9, 2023 /PRNewswire/ -- Halliburton Company (NYSE: HAL) and Core Laboratories Inc. (NYSE: CLB) today announced a strategic collaboration in the U.S. to compress the delivery time of ...

HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported fourth quarter 2025 revenue of $138,300,000. Core's operating income was ...

Core Laboratories (NYSE:CLB) reported fourth-quarter and full-year 2025 results that reflected modest top-line growth, continued shareholder returns, and a mix of strength in international demand ...

Reports Q3 revenue $134.4M, consensus $134.45M. CEO Larry Bruno stated, “In Q3 2024, Core Lab delivered solid sequential improvements in revenue, operating income, operating margins, incremental ...

Core Laboratories is in good financial health. At the last reporting period, the firm had $16 million of cash on hand and $180 million of long-term debt. 2022 net debt/adjusted EBITDA was elevated at ...

probability of performance condition for certain executive's share awards. (2) Three months ended June 30, 2025 and September 30, 2025 includes the write-down of inventory. (3) Three months ended June ...

AMSTERDAM, Nov. 1 /PRNewswire-FirstCall/ -- Core Laboratories N.V. (NYSE: CLB) ("Core Lab") today announced pricing of the offering by its U.S.- based, wholly owned ...